The Therapeutic Efficacy Of Interferon-beta-1b In The Patients With Relapsing-remitting Multiple Sclerosis

Objective:To evaluate the therapeutic efficacy and the safety of interferon-beta(IFN-beta-1b) in the patients with relapsing-remitting multiple sclerosis(RRMS)in Northeast China.Methods:We summarized cases of relapsing-remitting multiple sclerosis(RRMS)who hospitalized and followed-up in our department. In the total 46 patients,who diagnosedwith Mc Donald criteria(2010).Our cases were divided into two groups,Group A from theactive application of Subcutaneous injection of interferon IFN-beta-1b contained 23 patients.By screening, Group B contained another 23 patients who matchedwith the Group A in gender,age,diseaseduration,the patient’s expanded disability status score(EDSS),T2 MRI weighted imaging and Gd-DTPA lesions. We compared the index that EDSS scores,the number of relapse and the number of MRI lesion changing in two groups before enrolment and at the ends of 6months(T1),12months(T2),18months(T3),24months(T4).Group A regularly detected blood routine, liver function index and related indicators.Results:(1) Generaldata:Therewasnoobviousstatisticallysignificantin gender, age,disease duration,the patient’s expanded disability status score(EDSS),T2 MRI weighted imaging and Gd-DTPA lesions of two groups before enrolment(P>0.05).(2) EDSS score:In Group A,mean EDSS scores during treatment in different time pointswere significantly lower than that of the same previous period(P<0.05),scores showed a downward trend in the whole.While compared with the baseline score,there was an upward trend in Group B.There were differences between the two groups at different time points:At T0 and T1 time points, there was no significant difference in EDSS scores between Group A and Group B(P>0.05), however,at T2,T3,T4 time points,compared with Group B,the EDSS score of Group A was significantly lower,and the difference was statistically significant(P<0.05).(3) Annual average recurrence(ARR):During 2 year follow-up,the number of relapses during the treatment period was significantly lower than that of the previous in Group A,there was a significantreduction in the number of relapse(P<0.05).However,thenumber of relapses in Group B increased with the prolongation of the course of disease,After two years compared with Group B, the average number of years of recurrence was significantly reduced in Group A(P<0.05).(4) The number of MRI lesion:In Group A,the number of T2 lesion showed a significant downward trendduring treatment in different time points,there were significantly reduced than that of the previous(P<0.05).While the mean T2 lesion number of Group B showed increasing trend(P<0.05).Thenumberof gadolinium-enhanced T1 lesions respectively decreased in Group A at different time points.Group B was different,it had been showing a slow upward trend in the shape of a broken line on the whole.There were differences between the two groups at different time points:At T0 and T1 time points, there was no significant difference in the number of T2 lesion between Group A and Group B(P>0.05),however,at T2,T3,T4 time points,compared with Group B,the number of T2 lesion of Group A was significantly much less,and the difference was statistically significant(P<0.05).At T0 and T2 time points,there was no significant difference in the number of gadolinium-enhanced T1 lesion between Group A and Group B(P>0.05).However,at T1,T3,T4 time points,the number of gadolinium-enhanced T1 lesion Group A was significantly lower than Group B,and the difference was statistically significant(P<0.05).(5) Adverse reactions of IFN-beta-1b:There were 20 cases of adverse reactions in total.Flu-like symptoms and soreness scleroma at the injection site were the most common adverse reactions of IFN-β1b,their proportions were 21.7% and 30.4%,fever usually occurred in the early stage of drug use about 1 month.while soreness at the injection site occurred around 1.5 years.Meanwhile,3 cases of abnormal liver function and 2 cases of heart rate increase occurred in early treatment andreturned to normal with IFN-β1b subcutaneous injection.All adverse reactions were slight,and with theprolonged use of medication time gradually disappeared though the challenges of local pain for patients were relatively large.Conclusion: IFN-beta-1b was effective in the treatment of patients with RRMS in Northeast China,it can reduce clinical relapse and MRI lesion activity,improve EDSS score,slow the progression of physical disability.The side effects that IFN-beta-1b induced can be tolerated and almost at the application of the initial stage.Above proved to have good safety.